Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M3554 in Advanced Solid Tumors
NCT06641908Phase 1Recruiting
- Sponsor
- EMD Serono
- Start
- Nov 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of M3554 in soft tissue sarcoma (STS) and glioblastoma (GBM), sponsored by EMD Serono. Primary endpoint: Dose Limiting Toxicities and Adverse Events at 4 months. Started Nov 2024; status: recruiting.
02
Drugs
M3554
03
Conditions
soft tissue sarcoma (STS)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06641908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641908.